Show simple item record

dc.contributor.authorFernandez Egea, E
dc.contributor.authorworbe, yulia
dc.contributor.authorbernardo, Miguel
dc.contributor.authorRobbins, Trevor W
dc.description.abstractObjective: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients alt-hough the actual prevalence, phenomenology and risk factors remain unclear. The aim of the pre-sent study was to address the three aforementioned questions. Method: The electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined. Results: OCD prevalence was 47%, higher in patients on poly-pharmacy than on monotherapy (64% vs 31%; p=.001). Two OCI-R factors had significantly higher scores and distinct risk factors: checking behaviour (mean=5.1; SD=3.6) correlated with length of clozapine treatment (r=.21; p=.026), and obsessing factor (mean=4.8; SD=3.6) correlated with psychosis severity (r=.59; p=.001). These factors along with total OCI-R, did not correlate with either clozapine dose or plas-ma levels, after correcting for psychosis severity. Conclusion: Screening for OCD in clozapine patients, and probably in those treated with structur-ally similar drugs with potent antiserotoninergic properties, should be widely adopted by clinicians. Further research is needed to understand the pathophysiology underlying repetitive behavior onset in clozapine-treated patients.
dc.description.sponsorshipDr. Fernandez-Egea was supported by 2009 Young investigator award and intramural funding from CPFT/NIHR-CRN supported setting the database. Prof. Bernardo is funded by the Spanish Ministry of Science and Education, the Spanish Ministry of Economy and Competiveness, Centro de Inves-tigación Biomédica en Red de Salud Mental (CIBERSAM), from the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2014SGR441), from the Foundation European Group for Research In Schizophrenia (EGRIS) , and from the 7th Framework Program of the European Union. Dr. Y Worbe is supported by Association Française du syndrome de Gilles de la Tourette, Founda-tion de recherche Medicale and Dystonia Foundation for Medical Research (USA). Prof. TW Robbins' research is funded by a Wellcome Senior Investigator Award (104631/Z/14/Z). Work was completed at the Behavioural and Clinical Neuroscience Institute, which was supported by a joint award from the Medical Research Council and Wellcome Trust (G00001354).
dc.publisherCambridge University Press
dc.rightsAttribution 4.0 International
dc.subjecthabit formation
dc.subjectobsessive compulsive disorder
dc.titleDistinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
prism.publicationNamePsychological Medicine
dc.contributor.orcidFernandez Egea, Emilio [0000-0003-4128-8955]
dc.contributor.orcidRobbins, Trevor [0000-0003-0642-5977]
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (G1000183)
pubs.funder-project-idWellcome Trust (104631/Z/14/Z)
pubs.funder-project-idMedical Research Council (G0001354)
cam.orpheus.successThu Jan 30 13:00:32 GMT 2020 - The item has an open VoR version.

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International